{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:06:49Z","timestamp":1789625209694,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T00:00:00Z","timestamp":1314921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Blood operators have taken measures to reduce transfusion\u2010related acute lung injury (TRALI). We classified suspected TRALI cases reported to Canadian Blood Services from 2001 to 2009 and assessed the impact of TRALI reduction measures.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Using Canadian Consensus Conference definitions, cases were reviewed by two experts or, from 2006 to 2009, a TRALI Medical Review Group (TMRG). Detection of HLA antibodies was performed using the Luminex system starting in 2008. Measures implemented from 2007 to 2009 included use of predominantly male plasma, suspension of buffy coat platelets in male plasma, and deferral of females with a pregnancy history from plateletpheresis. The buffy coat production method was implemented from 2005 to 2008.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Reporting of all suspected TRALI cases, as well as cases classified as definite or possible, increased from 2001 to 2004, was stable from 2004 to 2007, and declined in 2008 to 2009. The decline was most marked for plasma\u2010associated cases, but occurred for all components. TMRG consensus on classification was achieved in 56% of cases. Cases identified as definitive or possible TRALI were significantly more likely to have donor antibody against a corresponding recipient antigen, compared to other cases.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Hemovigilance data demonstrated an initial increase in TRALI cases, likely due to increased adverse event reporting and awareness of TRALI, followed by a decrease in cases related to all components. TRALI prevention measures and possibly the switch to the buffy coat production method may have contributed to the decline. Classification of cases remains challenging.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2011.03330.x","type":"journal-article","created":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T13:11:32Z","timestamp":1314969092000},"page":"567-574","source":"Crossref","is-referenced-by-count":72,"title":["Transfusion\u2010related acute lung injury prevention measures and their impact at Canadian Blood Services"],"prefix":"10.1111","volume":"52","author":[{"given":"Yulia","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee\u2010Loong","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hannach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,2]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1983.128.1.185"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25686071434.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.10.001"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278135"},{"key":"e_1_2_8_6_2","volume-title":"Annual report 2003","author":"Serious Hazards of Transfusion","year":"2004"},{"key":"e_1_2_8_7_2","volume-title":"Fatalities reported to FDA following blood collection and transfusion","author":"Food and Drug Administration","year":"2011"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01403.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2004.04347.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06492.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02340.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00870.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02659.x"},{"key":"e_1_2_8_14_2","volume-title":"Final interim standard for standards for blood banks and transfusion services","author":"Mintz PD","year":"2005"},{"key":"e_1_2_8_15_2","volume-title":"Transfusion\u2010related acute lung injury","author":"Strong DM","year":"2006"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2010.05.005"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","unstructured":"LevinE CulibrkB Gy\u00f6ngy\u00f6ssy\u2010IssaMI WeissS ScammellK LeFresneW JenkinsC DevineDV.Implementation of buffy coat platelet component production: comparison to platelet\u2010rich plasma platelet production.Transfusion2008;48:2331\u20107.","DOI":"10.1111\/j.1537-2995.2008.01836.x"},{"key":"e_1_2_8_18_2","volume-title":"Annual report 2009","author":"Serious Hazards of Transfusion","year":"2010"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02652.x"},{"key":"e_1_2_8_20_2","unstructured":"Qu\u00e9bec hemovigilance committee.Comit\u00e9 d'hemovigilance 2007 and 2008 reports published 2008 and 2009. [cited 2011 Aug 22]. Available from: URL:http:\/\/www.msss.gouv.qc.ca\/hemovigilance\/"},{"key":"e_1_2_8_21_2","unstructured":"FDA Center for Biologics Evaluation & Research.Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009.2010. [cited 2010 Sep 23]. Available from: URL:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/TransfusionDonationFatalities\/UCM205620.pdf"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02345.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01948.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02715.x"},{"key":"e_1_2_8_25_2","unstructured":"StanworthS AndersonN BiancoC Foll\u00e9aG ChabanelA KellerAJ PinkJ EderA BenjaminR GoldmanM.International differences in production of blood components: implications for TRALI reduction. 31stInternational Congress of the ISBT Berlin Germany June 2010."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-271OC"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2008.00885.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2011.03330.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2011.03330.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:07:58Z","timestamp":1697314078000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2011.03330.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1537-2995.2011.03330.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03330.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,2]]}}}